A pocket-sized device automates multiplexed point-of-care RNA testing for rapid screening of infectious pathogens

Shu, Bowen; Li, Gang; Wu, Bin; Huang, Enqi; Wang, Yu; Li, Zhujun; He, Haoyan; Lei, Xiuxia; Xu, Banglao; Liu, Dayu

doi:10.1016/j.bios.2021.113145

Cited by 22 publications

(15 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Owing to the development of multiple RNA detection techniques ( Shu et al, 2021 ; Toden et al, 2021 ; Wang et al, 2021 ; Zhong et al, 2021a ), most RNAs have been found to lack the capacity to encode proteins. Although these RNAs do not directly translate into proteins ( Gupta et al, 2020 ), driving evidence clarifies that they play an essential role in biological functions ( Chen et al, 2020b ; Jantrapirom et al, 2021 ; Jin et al, 2021 ; Lai et al, 2021 ; Zhang et al, 2021b ).…”

Section: Introductionmentioning

confidence: 99%

Promising Advances in LINC01116 Related to Cancer

Xu¹,

Yu²,

Zhang³

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) are RNAs with a length of no less than 200 nucleotides that are not translated into proteins. Accumulating evidence indicates that lncRNAs are pivotal regulators of biological processes in several diseases, particularly in several malignant tumors. Long intergenic non-protein coding RNA 1116 (LINC01116) is a lncRNA, whose aberrant expression is correlated with a variety of cancers, including lung cancer, gastric cancer, colorectal cancer, glioma, and osteosarcoma. LINC01116 plays a crucial role in facilitating cell proliferation, invasion, migration, and apoptosis. In addition, numerous studies have recently suggested that LINC01116 has emerged as a novel biomarker for prognosis and therapy in malignant tumors. Consequently, we summarize the clinical significance of LINC01116 associated with biological processes in various tumors and provide a hopeful orientation to guide clinical treatment of various cancers in future studies.

show abstract

Section: Introductionmentioning

confidence: 99%

Promising Advances in LINC01116 Related to Cancer

Xu¹,

Yu²,

Zhang³

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…They are characterized by cost-efficiency, portability, low sample consumption (µL-fL), miniaturization (with dimensions of tens to hundreds of micrometers chambers), simplicity (no training is required), and multiplex detection (providing multiple spatially separated detection channels) [ 56 ]. In this section, we will discuss nucleic acid sensors on microfluidic platforms for multiplex diagnosis of infectious diseases [ 57 , 58 , 59 ].…”

Section: Multiplex Nucleic Acid Sensors On Microfluidic Platformsmentioning

confidence: 99%

Multiplex Detection of Infectious Diseases on Microfluidic Platforms

Chen

et al. 2023

Biosensors

View full text Add to dashboard Cite

Infectious diseases contribute significantly to the global disease burden. Sensitive and accurate screening methods are some of the most effective means of identifying sources of infection and controlling infectivity. Conventional detecting strategies such as quantitative polymerase chain reaction (qPCR), DNA sequencing, and mass spectrometry typically require bulky equipment and well-trained personnel. Therefore, mass screening of a large population using conventional strategies during pandemic periods often requires additional manpower, resources, and time, which cannot be guaranteed in resource-limited settings. Recently, emerging microfluidic technologies have shown the potential to replace conventional methods in performing point-of-care detection because they are automated, miniaturized, and integrated. By exploiting the spatial separation of detection sites, microfluidic platforms can enable the multiplex detection of infectious diseases to reduce the possibility of misdiagnosis and incomplete diagnosis of infectious diseases with similar symptoms. This review presents the recent advances in microfluidic platforms used for multiplex detection of infectious diseases, including microfluidic immunosensors and microfluidic nucleic acid sensors. As representative microfluidic platforms, lateral flow immunoassay (LFIA) platforms, polymer-based chips, paper-based devices, and droplet-based devices will be discussed in detail. In addition, the current challenges, commercialization, and prospects are proposed to promote the application of microfluidic platforms in infectious disease detection.

show abstract

“…To allow the assay to be suitable for POCT, these steps should be performed with a very simple instrument or without any instrument. [13][14][15][16][17] Usually an instrument is needed for amplification even if using isothermal amplification methods, such as recombinase polymerase amplification (RPA) and loopmediated isothermal amplification (LAMP), [18][19][20][21][22] and thus visualized detection of amplicons is the key to enable a method for POCT. [23][24][25][26] Visualized detection used for POCT is mainly based on colorimetric indicators, lateral flow strip (LFS), and gold nanoparticles (AuNPs) for signal read-out.…”

Section: Introductionmentioning

confidence: 99%